NIDCR's Fall 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Fall 2021 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NICDR News
Science Advances
NIDCR News
5 Q&As About “Oral Health in America: Advances and Challenges”
NIDCR issued a brief Q&A regarding details of the forthcoming report Oral Health in America: Advances and Challenges, which will be published in Fall 2021. This comprehensive report will examine improvements in oral health over the past two decad...
Source: NIDCR Science News - September 1, 2021 Category: Dentistry Source Type: news
CT Imaging May Help Distinguish COVID-19 From Interstitial Lung Disease CT Imaging May Help Distinguish COVID-19 From Interstitial Lung Disease
Computed tomography (CT) could be used to help distinguish COVID-19 from systemic sclerosis-related interstitial lung disease (SSc-ILD), researchers suggest.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 13, 2021 Category: Radiology Tags: Infectious Diseases News Source Type: news
Rituximab Seems Safe and Effective for Systemic Sclerosis Rituximab Seems Safe and Effective for Systemic Sclerosis
Rituximab seemed to be a safe and effective treatment for systemic sclerosis in a placebo-controlled validation trial in Japan.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news
New Biomarkers May Predict Course of ILD in Systemic Sclerosis New Biomarkers May Predict Course of ILD in Systemic Sclerosis
Radiographic assessment of interstitial lung disease (ILD) progression and proteins from bronchoalveolar lavage may independently provide better insight into prognoses of patients with systemic sclerosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Online mental health therapy significantly aids the isolated, immunosuppressed in pandemic
(Michigan Medicine - University of Michigan) People with the rare autoimmune disease scleroderma, who likely experience more serious isolation during a global pandemic, saw their anxiety and depression improve after receiving online mental health intervention through an international study. Researchers say the program could be extended to many vulnerable patient populations moving forward. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 16, 2021 Category: Infectious Diseases Source Type: news
The UCLA GIT 2.0 as a Decision Aid in Systemic Sclerosis The UCLA GIT 2.0 as a Decision Aid in Systemic Sclerosis
Learn more about the potential role the UCLA GIT 2.0 could have in the management of systemic sclerosis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 10, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
Stabilization of lung function independent of the extent of quantitative radiographic interstitial lung disease or fibrosis at baseline (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 23, 2021 Category: Respiratory Medicine Tags: Dermatology, Pharmacy, Pulmonology, Radiology, Rheumatology, Journal, Source Type: news
Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
FRIDAY, April 23, 2021 -- Tocilizumab prevents progression of interstitial lung disease in patients with early systemic sclerosis (SSc), according to a study recently published in Arthritis& Rheumatology.
David Roofeh, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2021 Category: Pharmaceuticals Source Type: news
For scleroderma, algorithm helps better screen for fatal complication
(Michigan Medicine - University of Michigan) A portion of people with the scleroderma develop pulmonary arterial hypertension, which can cause the heart to weaken and fail. Current screening methods may miss one in three patients with this sometimes fatal complication. But one computer algorithm, according to this study, will significantly improve the accuracy and help physicians treat it earlier. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 21, 2021 Category: International Medicine & Public Health Source Type: news
Screening for skin disease on your laptop
(University of Houston) A University of Houston biomedical engineer is reporting a new deep neural network architecture - to be used on a standard laptop - that provides early diagnosis of systemic sclerosis (SSc), a rare autoimmune disease marked by hardened or fibrous skin and internal organs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 6, 2021 Category: International Medicine & Public Health Source Type: news
Combination therapy in systemic sclerosis-related pulmonary arterial hypertension: survival benefits at high cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news
Repurposing tocilizumab in scleroderma patients may prevent early lung disease
(Michigan Medicine - University of Michigan) A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 31, 2021 Category: International Medicine & Public Health Source Type: news
Tocilizumab Scores FDA Approval for SSc-ILD Tocilizumab Scores FDA Approval for SSc-ILD
Tocilizumab is the first biologic to be approved by the agency for adults with systemic sclerosis –associated interstitial lung disease, a rare, potentially life-threatening condition.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 8, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news
Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no cure. ...
Source: Roche Investor Update - March 5, 2021 Category: Pharmaceuticals Source Type: news
Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no cure. ...
Source: Roche Media News - March 5, 2021 Category: Pharmaceuticals Source Type: news
